Oral administration to five postmenopausal women of dl-norgestrel (0.075 mg/d for 7 wk) reduced mean fasting plasma levels of triglycerides by 29% (P < 0.001), VLDL triglycerides by 39% (P < 0.01), and VLDL apo B by 26% (P < 0.05), while lowering mean total cholesterol by 7% (P < 0.06). To explain these observations the kinetics of VLDL and LDL apo B turnover were studied by injecting autologous "25I-labeled VLDL and "311-labeled LDL under control conditions and again in the fourth week of a 7-wk course of dl-norgestrel. VLDL apo B pool size fell by an average of 27% (1.2 vs 1.7 mg/kg, P < 0.06) and production of apo B by 18% (18 vs 22 mg/kg per d, P < 0.05) with unchanged fractional catabolic rate. Production of LDL apo B increased 36% with dl-norgestrel ( 12 vs 9.4 mg/kg per d, P < 0.05), but this was compensated by a 36% increase in fractional catabolic rate of LDL apo B (0.33 vs 0.25 pools/d, P < 0.005), thereby maintaining pool size. Lipoprotein (a) fell by an average of 12% (16 vs 18 mg/dl, P < 0.06). dl-Norgestrel reduced VLDL triglycerides (40 vs 64 mg/dl, P < 0.05), intermediate density lipoprotein cholesterol (14 vs 19 mg/dl, P < 0.02), IDL apo B (5.3 vs 7.2 mg/dl, P < 0.05), and VLDL cholesterol (3.1 vs 5.1 mg/dl, 0.10 > P > 0.05), in parallel with the reductions in VLDL apo B production and pool size. dl-Norgestrel significantly lowered the production rate of VLDL apo B, thereby decreasing plasma VLDL and intermediate density lipoprotein concentrations. (J. Clin. Invest. 1993. 92:456461.)
Introduction
The synthetic progestin dl-norgestrel is used widely pharmaceutically in combination with estrogen in the formulation of oral contraceptives ( 1) and has also recently been tested in continuous low dosage together with estradiol-17f3 in the hormonal replacement of symptomatic estrogen-deficient postmenopausal women (2) . Combined low dosages of dl-norgestrel and estradiol-1713 lower plasma cholesterol and triglycerides in postmenopausal women by increasing fractional catabolism of VLDL and reducing production of LDL (3) . However, the specific contribution of dl-norgestrel to the ob-served lowering of lipids is unknown. Although most reports find that oral contraceptives containing dl-norgestrel lower plasma triglycerides (4, 5) , this has not been universal (6) (7) (8) . Levonorgestrel, the active isomer of dl-norgestrel, lowers plasma total and VLDL triglycerides in intact female rats when given alone (9) , but not when combined with estradiol (10) . The reduction of VLDL apo B levels with levonorgestrel in intact female rats is attributable to enhanced fractional catabolism ofVLDL ( 11 ) . However, inhibition ofhepatic triglyceride synthesis could also contribute to reduction ofplasma triglycerides because levonorgestrel inhibits incorporation of labeled glycerol and fatty acids into rat hepatocyte triglycerides and reduces their incorporation into triglycerides released into the incubation medium (9) . This appears to involve, at least in part, inhibition of the hepatic glycerol-3-phosphate acyltransferase (12) . Prophylaxis against postmenopausal coronary heart disease, osteoporosis, endometrial cancer, and stroke (13) (14) (15) 1  50  163  62  219  213  142  98  14  13  2  64  162  73  283  229  198  155  21  19  3  58  160   74  192  182  138  92  28  22  4  76  152  62  232  224  140  99  9.3  7.8  5  68  151  52  279  270  117  88  20  19  Mean  63  158  65  241 (21, 24 ) and apo B isolated from each lipoprotein fraction by isopropanol precipitation and its specific activity determined as previously described (25) . Analyses. The structure of the kinetic model and equations used to calculate the kinetic parameters have been described in detail previously (11) . The principal assumptions of this model are that (a) apo B is an integral part ofeach ofVLDL, IDL, and LDL, is nonexchangeable and therefore provides an accurate measure of the metabolism ofthese lipoproteins; (b) the metabolism of the tracer is identical to that of the tracee; (c) the production rate or flux of VLDL apo B is defined as representing input of apo B primarily into the larger, rapidly turning over, primary metabolic compartment (pool 1); (d) all apo B catabolism occurs from pool 1 either directly or after passing through either pool 2 or 3; (e) all subpopulations ofVLDL are isolated for labeling and that the initial injected activity is proportional to the mass of apo B in each population; (f) the two-pool model used for LDL apo B analysis is characterized by a plasma compartment and extravascular exchange compartment; and (g) at the time ofinjection all LDL apo B radioactivity is introduced into the plasma compartment and irreversible loss of LDL apo B occurs from the same compartment.
As in earlier studies in humans and rats, the specific activity curves of VLDL apo B were best described by the three-pool model of Goodman et al. (26), modified according to Skinner (27) , that provided a better fit by residual error testing than a two-pool model. The kinetic parameters of this model for VLDL were calculated as previously described (3, 11, 26) . As in a previous study (3), there was no evidence for a third pool for LDL apo B and the specific activity curves of LDL apo B were analyzed and kinetic parameters calculated using the conventional two-pool model of Gurpide et al. (21, (28) (29) (30) . This yielded values for flux rates through pool 1, irreversible fractional catabolic rate (FCR = kA, assuming that catabolism from other pools is negligible) (28) , and mass in pool 1. The mass of plasma apo B in VLDL and LDL was determined by electroimmunoassay as previously described (31) . Lp(a) was measured using Macra Lp(a) Kit obtained from Terumo Medical Corp., Elkton, MD. The intraassay coefficients of variation for apo B and Lp(a) were 4.5 and 4.7%, respectively. VLDL apo B pool size was determined independently from the plasma concentration of VLDL apo B (31) multiplied by the plasma volume taken as 36 mg/kg body wt (32) . IDL apo B concentration was also determined by electroimmunoassay (31 ) . The FCR was calculated as: kA = aft//(a + 3-kAA) (28) .
The percentage of LDL apo B that was derived from IDL apo B was calculated as: 1 -(area under the '251I-LDL apo B specific activity curve/area under the 1251-IDL apo B specific activity curve); (23, 33) .
Concentrations of cholesterol and triglycerides in the chloroformmethanol extract of whole plasma were determined as previously described (22), except that diagnostic kits from Boehringer Mannheim GmbH Diagnostica, Montreal, Canada (C-system kit for cholesterol and test combination kit for triglycerides) were used to measure cholesterol content of fasting plasma VLDL, IDL, and LDL and triglyceride content of VLDL during the turnover studies because of the small amounts of material available for assay. HDL cholesterol was measured after precipitation with heparin-manganese chloride (34) . Values from control and treatment periods were compared using Student's Values for each subject were based upon fasting blood plasma samples obtained immediately before injection of autologous labeled 125I-VLDL and "3'I-LDL at the beginning of each turnover study. * Different from control, P < 0.05. * Different from control, P < 0.02.
paired two-tailed t test (35) or the nonparametric sign test (36) if the difference narrowly failed to achieve P < 0.05, as specifically noted.
Results
The oral administration of dl-norgestrel (0.075 mg/d for 7 wk) significantly lowered mean plasma triglycerides (P < 0.05, (31) . Plasma volume was assumed to be 36 ml/kg (32 Values for the specific activities of '251-labeled apo B in VLDL, IDL, and LDL over 72 h after injection of '251-labeled VLDL during dl-norgestrel treatment versus control are shown in Fig. 1 . The kinetic parameters of VLDL turnover calculated from the '251I-labeled VLDL apo B decay curves are shown in Table III . During the treatment versus control periods, there were no significant differences in FCR; however, mean VLDL apo B production rate fell significantly by 18±5% (P < 0.05) and mean VLDL apo B pool size determined by kinetic analysis fell by 27±12% (P < 0.06 by sign test). Fig. 2 illustrates the effect of dl-norgestrel administration on the percent decrease of the '31I-labeled LDL apo B specific activity from the plasma for a representative subject. The kinetic parameters of LDL turnover calculated from the '31I-labeled LDL decay curves using the two-pool model of Gurpide et al. (27) are shown in Table IV . Based on these curves the half-life of phase I, but not phase II, was significantly shorter during the treatment versus control (39±4 vs 21+2 h, P < 0.01 ). The FCR of LDL apo B was significantly increased by an average of 36±7% during dl-norgestrel treatment versus control (0.33±0.01 vs 0.25±0.02 pools/d, P < 0.005). The enhancement of LDL apo B catabolism was not accompanied by any systematic change in pool size of LDL apo B because LDL apo B production rate increased reciprocally by an average of 36±13% during dl-norgestrel treatment versus control ( 12±1.4 vs 9.4±1.7 mg/kg per d, P < 0.05).
Evaluation of product-precursor relationships (37) between lipoprotein fractions indicated that VLDL were the sole precursors of IDL. As illustrated in a representative subject (Fig. 1) , the decay curves of VLDL apo B consistently intersected those of IDL apo B at their peaks during both treatment and control periods. However, the LDL apo B specific activity curves consistently reached their peaks before they were intersected by their corresponding IDL curves. This is consistent with LDL entering the circulation directly (33) and/or via small, a rapidly turning over, hepatogenous pool(s) of VLDL apo B (38) which is not traceable with exogenous iodine labeling (25) . The relative importance of the two pathways in the present experiments could not be determined. Comparisons of the areas under the specific activity curve as described by Goldberg et al. (33) indicated that LDL production derived from plasma VLDL and IDL could account for up to half of total LDL apo B production during treatment versus control (50 vs (Table II) . Although low dosage dl-norgestrel had no detectable effect on HDL cholesterol during the 7-wk period of observation, combined administration of low doses of dl-norgestrel and estradiol-1 7,3 was found to significantly lower HDL cholesterol (2), as have sixfold higher norgestrel doses (39) . The present finding of increased plasma LDL apo B turnover with constant plasma concentration during administration of dl-norgestrel alone (Table IV) strongly contrasts with the reductions in LDL apo B production and concentration that were observed when a similar dose of dl-norgestrel was given together with estradiol-17# to postmenopausal women (3), but is consistent with enhanced production of LDL observed during progesterone treatment of female baboons (40) . The low dosage dl-norgestrel given alone increased mean LDL catabolism to the same extent (i.e., 36%) as 2 mg/d estradiol in another study ofpostmenopausal women (41) . Whereas estradiol increased LDL apo B production by only 21% and lowered LDL apo B (41 ), dl-norgestrel increased LDL apo B production by 36% maintaining its concentration (Table IV) . The known effects of estradiol on lipoprotein metabolism (41, 42) fail to explain the differences in metabolic effects observed between administration of dl-norgestrel alone versus dl-norgestrel combined with estradiol-17fB (3) and the metabolic basis of the interaction ofestradiol and dl-norgestrel in inhibiting LDL apo B production (3) remains unclear. It is conceivable that dl-norgestrel given alone could bind to estrogen receptors (43) and/or other estrogen-or progesterone-responsive elements of other genes and induce estrogen-like effects on LDL metabolism. Other mechanisms of hormone action may also be possible. For instance, antiglucocorticoid effects have been attributed to progestin binding to glucocorticoid receptors (44) . Levonorgestrel alone reduces plasma triglycerides in female rats in vivo and inhibits hepatocyte triglyceride synthesis in vitro, but not in the presence of estradiol (10) . Nevertheless, plasma cholesterol is not reduced in the rat by either treatment.
The present finding of a slight, but consistent decrease in fasting plasma Lp(a) with administration of the present low dosage of dl-norgestrel could have implications for the reduction of coronary heart disease in postmenopausal women resulting from elevated plasma Lp(a) (16, 17) . The change in Lp(a) concentration is in the same direction, though the changes are smaller than with an 80-fold higher dose of stanozolol (45) . Although dl-norgestrel shares HDL lowering effects with stanozolol, the actual mechanism underlying the reduction of Lp(a) by these agents is unknown.
The present findings with low dosage dl-norgestrel in women with ovarian failure provide new insights into progestin effects on lipoprotein metabolism and may have implications both for the design of progestin-only and combined estrogen/ progestin oral contraceptives for premenopausal women and the formulation ofperhaps more widely acceptable continuous low dosage female hormonal replacement therapy in postmenopausal women (2) , including those in whom moderate hypertriglyceridemia (46) may pose a risk of coronary heart disease and more severe hypertriglyceridemia may pose a risk ofestrogen-induced pancreatitis (47, 48 
